Cognition Therapeutics Operating Income Over Time
| CGTX Stock | USD 1.04 0.05 4.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cognition Therapeutics Performance and Cognition Therapeutics Correlation. Cognition | Build AI portfolio with Cognition Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cognition Therapeutics. Projected growth potential of Cognition fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cognition Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Cognition Therapeutics is measured differently than its book value, which is the value of Cognition that is recorded on the company's balance sheet. Investors also form their own opinion of Cognition Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cognition Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cognition Therapeutics' market value can be influenced by many factors that don't directly affect Cognition Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cognition Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cognition Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cognition Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Cognition Therapeutics and related stocks such as Creative Medical Tec, Aprea Therapeutics, and Adial Pharmaceuticals Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CELZ | (1.4 K) | (19.8 K) | (20.1 K) | (20.1 K) | (19.4 K) | (20.8 K) | (766.1 K) | (1.2 M) | (1.1 M) | (1.1 M) | (1.1 M) | (3.1 M) | (10.2 M) | (5.6 M) | (5.7 M) | (5.2 M) | (4.9 M) |
| APRE | (3.2 M) | (21.3 K) | (21.3 K) | (246.5 K) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (16.5 M) | (29.5 M) | (52.8 M) | (37.4 M) | (113.4 M) | (15.5 M) | (14.3 M) | (12.9 M) | (13.5 M) |
| ADIL | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (410.8 K) | (995.3 K) | (7 M) | (8.2 M) | (10.9 M) | (19.3 M) | (10.9 M) | (6.9 M) | (8.3 M) | (7.5 M) | (7.8 M) |
| KPRX | (5.9 M) | (5.9 M) | (5.9 M) | (3.1 M) | (2.5 M) | (6.7 M) | (13.3 M) | (14.6 M) | (10.8 M) | (7 M) | (6.9 M) | (14.2 M) | (12.3 M) | (12.6 M) | 4.5 M | 4.1 M | 4.3 M |
| CDIO | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (620.4 K) | (4.5 M) | (7.2 M) | (8.4 M) | (7.5 M) | (7.2 M) |
| PHIO | (12.8 M) | (12.8 M) | (13 M) | (20.9 M) | (8.8 M) | (10.2 M) | (9 M) | (14.1 M) | (7.4 M) | (9 M) | (8.8 M) | (13.5 M) | (11.5 M) | (10.8 M) | (7.4 M) | (8.5 M) | (8.9 M) |
Cognition Therapeutics and related stocks such as Creative Medical Tec, Aprea Therapeutics, and Adial Pharmaceuticals Operating Income description
Operating Income is the amount of profit realized from Cognition Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cognition Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Cognition Therapeutics | CGTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2500 Westchester Ave, |
| Exchange | NASDAQ Exchange |
USD 1.04
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.